In this section : Covid-19
Molnupiravir
Sotrovimab
Conscious Proning
Covid-19 Basics
Remdesivir
Thromboprophylaxis
Identifying Patients in the Highest Risk Groups
Steroids for Patients with Covid-19 Infection
IL-6 Inhibitors – Tocilizumab or Sarilumab
Baricitinib
Paxlovid (Nirmatrelvir/Ritonavir)
Covid-19 Sick Day Rules for Patients with Primary Adrenal Insufficiency
Sotrovimab
Last updated 18th July 2024
Background
- Currently advised for use in hospitalised patients with COVID-19
- not requiring oxygen, AND
- are either in an at-risk group or who have been identified as at risk of destabilisation of their current condition due to their COVID-19 infection.
- Discuss during the working day with relevant consultant and ward pharmacist and consider prescribing if the following criteria are met:
- Ritonavir & Nirmatrelvir are NOT suitable
- Within 5 days of symptom onset
- Weight >40kg
Dose
- A single dose of 500mg administered as an IV infusion over 30 minutes.
Cautions
- Hypersensitivity reactions, including anaphylaxis, have been reported with sotrovimab.
- Ensure appropriate anaphylaxis support is readily available before commencing infusion, and that patients are monitored for signs of hypersensitivity for 24 hours.
- If the patient goes home within that timeframe, ensure they are aware of potential symptoms (nausea, chills, dizziness, syncope, rash, urticaria, flushing).
Availability
- Available from pharmacy during usual opening hours (0900 – 1700). It will be sent up with a filter and preparation instructions.
Links
- NICE COVID-19 rapid guideline: Managing COVID-19
- SEHD Covid Therapeutic Alert 2023 1 – Publication of NICE Multiple Technology Appraisal (MTA) – Treatment Recommendations for Covid 19
- NICE TA878 – Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Content by Alison Moore